Annexon (ANNX) Competitors

Annexon logo
$3.47 -0.10 (-2.80%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.43 -0.04 (-1.15%)
As of 07:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ANNX vs. ACAD, IDYA, DNLI, CELC, and VCEL

Should you buy Annexon stock or one of its competitors? Annexon's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), IDEAYA Biosciences (IDYA), Denali Therapeutics (DNLI), Celcuity (CELC), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annexon compare to ACADIA Pharmaceuticals?

Annexon (NASDAQ:ANNX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Annexon currently has a consensus price target of $15.29, suggesting a potential upside of 340.51%. ACADIA Pharmaceuticals has a consensus price target of $31.34, suggesting a potential upside of 71.08%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annexon
2 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
ACADIA Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.72

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Annexon. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 15 mentions for Annexon. ACADIA Pharmaceuticals' average media sentiment score of 0.24 beat Annexon's score of 0.10 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ACADIA Pharmaceuticals
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Annexon has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A-$206.69M-$1.04N/A
ACADIA Pharmaceuticals$1.07B2.95$391M$2.118.68

ACADIA Pharmaceuticals has a net margin of 30.13% compared to Annexon's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 8.90% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
AnnexonN/A -106.82% -76.75%
ACADIA Pharmaceuticals 30.13%8.90%6.86%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Annexon on 12 of the 14 factors compared between the two stocks.

How does Annexon compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Annexon has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -1,157.18%. IDEAYA Biosciences' return on equity of -39.78% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
IDEAYA Biosciences-1,157.18% -39.78% -36.25%
Annexon N/A -106.82%-76.75%

IDEAYA Biosciences currently has a consensus price target of $49.55, indicating a potential upside of 80.82%. Annexon has a consensus price target of $15.29, indicating a potential upside of 340.51%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEAYA Biosciences
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
Annexon
2 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40

IDEAYA Biosciences has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Annexon has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Annexon. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA Biosciences$218.71M12.11-$113.70M-$4.49N/A
AnnexonN/AN/A-$206.69M-$1.04N/A

In the previous week, Annexon had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 15 mentions for Annexon and 14 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.34 beat Annexon's score of 0.10 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEAYA Biosciences
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

IDEAYA Biosciences beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Annexon compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

92.9% of Denali Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Annexon has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$330.53M8.73-$512.54M-$1.73N/A
AnnexonN/AN/A-$206.69M-$1.04N/A

Denali Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Annexon has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Denali Therapeutics' return on equity of -54.94% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
Denali TherapeuticsN/A -54.94% -42.15%
Annexon N/A -106.82%-76.75%

Denali Therapeutics presently has a consensus target price of $35.71, indicating a potential upside of 98.41%. Annexon has a consensus target price of $15.29, indicating a potential upside of 340.51%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82
Annexon
2 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Annexon had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 15 mentions for Annexon and 13 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.53 beat Annexon's score of 0.10 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Denali Therapeutics beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Annexon compare to Celcuity?

Annexon (NASDAQ:ANNX) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

63.3% of Celcuity shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Annexon had 11 more articles in the media than Celcuity. MarketBeat recorded 15 mentions for Annexon and 4 mentions for Celcuity. Celcuity's average media sentiment score of 0.64 beat Annexon's score of 0.10 indicating that Celcuity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Celcuity
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Celcuity is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A-$206.69M-$1.04N/A
CelcuityN/AN/A-$177.04M-$4.71N/A

Annexon presently has a consensus target price of $15.29, indicating a potential upside of 340.51%. Celcuity has a consensus target price of $151.79, indicating a potential upside of 161.65%. Given Annexon's higher possible upside, research analysts plainly believe Annexon is more favorable than Celcuity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annexon
2 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
Celcuity
2 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.69

Annexon has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Annexon's return on equity of -106.82% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
AnnexonN/A -106.82% -76.75%
Celcuity N/A -1,522.54%-42.11%

Summary

Celcuity beats Annexon on 7 of the 12 factors compared between the two stocks.

How does Annexon compare to Vericel?

Annexon (NASDAQ:ANNX) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Vericel has a net margin of 10.27% compared to Annexon's net margin of 0.00%. Vericel's return on equity of 9.09% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
AnnexonN/A -106.82% -76.75%
Vericel 10.27%9.09%6.68%

In the previous week, Annexon and Annexon both had 15 articles in the media. Vericel's average media sentiment score of 0.75 beat Annexon's score of 0.10 indicating that Vericel is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vericel
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Annexon presently has a consensus price target of $15.29, suggesting a potential upside of 340.51%. Vericel has a consensus price target of $62.00, suggesting a potential upside of 7.12%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annexon
2 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
Vericel
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

Vericel has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A-$206.69M-$1.04N/A
Vericel$276.26M10.69$16.52M$0.6490.44

Annexon has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Vericel has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Summary

Vericel beats Annexon on 9 of the 12 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANNX vs. The Competition

MetricAnnexonBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$681.03M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / SalesN/A15.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book4.634.184.453.72
Net Income-$206.69M-$24.15M$3.52B$393.10M
7 Day Performance-17.18%-7.81%-5.93%-5.77%
1 Month Performance1.76%-5.99%-4.58%-7.14%
1 Year Performance8.44%-8.09%-1.94%-7.46%

Annexon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANNX
Annexon
3.346 of 5 stars
$3.47
-2.8%
$15.29
+340.5%
+14.9%$681.03MN/AN/A92
ACAD
ACADIA Pharmaceuticals
4.744 of 5 stars
$18.14
-1.3%
$31.55
+73.9%
-23.7%$3.17B$1.07B8.60798
IDYA
IDEAYA Biosciences
3.0606 of 5 stars
$31.49
-3.8%
$49.55
+57.3%
-17.8%$3.16B$218.71MN/A145
DNLI
Denali Therapeutics
3.7006 of 5 stars
$18.89
-4.3%
$36.15
+91.4%
+3.6%$3.16B$330.53MN/A507
CELC
Celcuity
2.5173 of 5 stars
$64.17
-0.2%
$151.79
+136.5%
-37.1%$3.16BN/AN/A155

Related Companies and Tools


This page (NASDAQ:ANNX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners